Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.
Nasdaq14d
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
The company currently markets Auvelity (AXS-05) for treating major depressive disorder (MDD) and Sunosi (solriamfetol) for treating narcolepsy. Auvelity was launched in the United States in 2022 ...
Medical News Today17d
Sunosi: Pregnancy and breastfeeding information
It’s not known whether Sunosi (solriamfetol) is safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine ...
Business Insider25d
Strong Financial Performance and Promising Future: Axsome Therapeutics Receives Buy Rating from Analyst
The company’s preliminary fourth-quarter and full-year 2024 financial results have surpassed expectations, showcasing significant growth in product sales, particularly with Auvelity and Sunosi.
Sports Illustrated25d
Super Bowl Logos Through the Years: A Look at How They’ve Evolved
Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...